Xiaolong P. Yan

13 Hangkong Road
Wuhan, 430030, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 163 publications

Ensartinib in Resected ALK-Positive Non-Small-Cell Lung Cancer.

Ensartinib in Resected ALK-Positive Non-Small-Cell Lung Cancer.

Journal: The New England journal of medicine

Published: July 08, 2026

The role of mitochondrial energy metabolism in drug resistance and prognosis of lung adenocarcinoma: a multi-omics and machine learning strategy for predictive and personalized therapy.

The role of mitochondrial energy metabolism in drug resistance and prognosis of lung adenocarcinoma: a multi-omics and machine learning strategy for predictive and personalized therapy.

Journal: Frontiers in medicine

Published: May 27, 2026

Establishment and evaluation of path planning strategy and execution methods for posterior tooth preparation using an autonomous oral surgical robot

Establishment and evaluation of path planning strategy and execution methods for posterior tooth preparation using an autonomous oral surgical robot

Journal: Zhonghua kou qiang yi xue za zhi = Zhonghua kouqiang yixue zazhi = Chinese journal of stomatology

Published: April 29, 2026

Alternating Shear Force of Respiration Regulates Cell Interactions of Fibroblasts and Macrophages to Promote Soft Tissue Integration of Chest Wall Polyetheretherketone Implants.

Alternating Shear Force of Respiration Regulates Cell Interactions of Fibroblasts and Macrophages to Promote Soft Tissue Integration of Chest Wall Polyetheretherketone Implants.

Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)

Published: April 23, 2026

A Cellulose-Derived Polymer Additive for Stabilizing Thick Cathodes in All-Solid-State Batteries.

A Cellulose-Derived Polymer Additive for Stabilizing Thick Cathodes in All-Solid-State Batteries.

Journal: Angewandte Chemie (International ed. in English)

Published: March 07, 2026

Lymph Node Yield and Disease-Free Survival After Neoadjuvant Chemoimmunotherapy for Esophageal Squamous Cell Carcinoma: A Multicenter, Retrospective Cohort Study.

Lymph Node Yield and Disease-Free Survival After Neoadjuvant Chemoimmunotherapy for Esophageal Squamous Cell Carcinoma: A Multicenter, Retrospective Cohort Study.

Journal: Annals of surgical oncology

Published: January 29, 2026

Survival Differences Among Non-pCR Patients with Distinct Pathological Outcomes After Neoadjuvant Therapy for Esophageal Squamous Cell Carcinoma.

Survival Differences Among Non-pCR Patients with Distinct Pathological Outcomes After Neoadjuvant Therapy for Esophageal Squamous Cell Carcinoma.

Journal: The Journal of thoracic and cardiovascular surgery

Published: January 22, 2026

Survival differences among patients with nonpathological complete response with distinct pathological outcomes after neoadjuvant therapy for esophageal squamous cell carcinoma.

Survival differences among patients with nonpathological complete response with distinct pathological outcomes after neoadjuvant therapy for esophageal squamous cell carcinoma.

Journal: The Journal of thoracic and cardiovascular surgery

Published: January 22, 2026

Neoadjuvant or conversion anti-PD-1/PD-L1 immunotherapy combined with chemotherapy improves 2-year survival and achieves high pathological complete response rate in patients with stage IIB-IIIB small-cell lung cancer.

Neoadjuvant or conversion anti-PD-1/PD-L1 immunotherapy combined with chemotherapy improves 2-year survival and achieves high pathological complete response rate in patients with stage IIB-IIIB small-cell lung cancer.

Journal: Translational lung cancer research

Published: January 01, 2026

Three-dimensional printed PCL/nHA scaffolds promote soft tissue functional fibrosis to repair chest wall defect via Piezo1/Ca2+ signal during respiratory motion.

Three-dimensional printed PCL/nHA scaffolds promote soft tissue functional fibrosis to repair chest wall defect via Piezo1/Ca2+ signal during respiratory motion.

Journal: Bioactive materials

Published: December 24, 2025

TIMELESS Promotes LUAD Growth via Suppressing Transferrin-Mediated Ferroptosis and Reprograms the Tumor Microenvironment against Anti-PD-1 Immunotherapy.

TIMELESS Promotes LUAD Growth via Suppressing Transferrin-Mediated Ferroptosis and Reprograms the Tumor Microenvironment against Anti-PD-1 Immunotherapy.

Journal: Cancer communications (London, England)

Published: December 21, 2025

Association between patient-reported outcomes and pathological response in neoadjuvant chemoimmunotherapy-a post hoc analysis of the TD-FOREKNOW trial.

Association between patient-reported outcomes and pathological response in neoadjuvant chemoimmunotherapy-a post hoc analysis of the TD-FOREKNOW trial.

Journal: Translational lung cancer research

Published: December 11, 2025

Showing 1-12 of 163

Last Updated: 09/26/2026